Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00290433 · ClinicalTrials.gov registry record · Phase 2
Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT00290433: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00290433 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00290433, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if treatment with two types of chemotherapy combinations can help to control peripheral T-cell lymphoma.
Interventions
- DRUG Cyclophosphamide
- DRUG Mesna
- DRUG Vincristine
- DRUG Methotrexate
- DRUG Ara-C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2003-09 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00290433
The ClinicalTrials.gov registry entry for NCT00290433 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00290433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00290433 about?
NCT00290433 is a clinical study titled "Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma". The goal of this clinical research study is to learn if treatment with two types of chemotherapy combinations can help to control peripheral T-cell lymphoma.
What is the current status of trial NCT00290433?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2003-09. Estimated completion is 2015-07.
What interventions are being tested in trial NCT00290433?
The interventions under investigation include: Cyclophosphamide (DRUG), Mesna (DRUG), Vincristine (DRUG), Methotrexate (DRUG), Ara-C (DRUG).
Who is sponsoring clinical trial NCT00290433?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.